28121744|t|Everolimus for Treatment of Pseudomyogenic Hemangioendothelioma
28121744|a|Pseudomyogenic hemangioendothelioma (PMH) is a recently described vascular neoplasm that occurs most commonly in the soft tissue of the distal extremities of young adults. Metastatic PMH can be fatal and there are no effective medications. We describe a case of a 15-year-old boy with metastatic PMH, who responded to treatment with everolimus, a mammalian target of rapamycin inhibitor. Immunohistochemistry showed that mammalian target of rapamycin was expressed in PMH biopsy specimens, which may explain the reduction in PMH tumor size following treatment.
28121744	0	10	Everolimus	T103	UMLS:C0541315
28121744	15	24	Treatment	T058	UMLS:C0087111
28121744	28	63	Pseudomyogenic Hemangioendothelioma	T038	UMLS:C0018915
28121744	64	99	Pseudomyogenic hemangioendothelioma	T038	UMLS:C0018915
28121744	101	104	PMH	T038	UMLS:C0018915
28121744	130	147	vascular neoplasm	T038	UMLS:C0282607
28121744	181	192	soft tissue	T017	UMLS:C0225317
28121744	247	250	PMH	T038	UMLS:C0018915
28121744	291	302	medications	T103	UMLS:C0013227
28121744	360	363	PMH	T038	UMLS:C0018915
28121744	369	391	responded to treatment	T201	UMLS:C0521982
28121744	397	407	everolimus	T103	UMLS:C0541315
28121744	411	450	mammalian target of rapamycin inhibitor	T103	UMLS:C2746052
28121744	452	472	Immunohistochemistry	T058	UMLS:C0021044
28121744	485	514	mammalian target of rapamycin	T103	UMLS:C1307407
28121744	519	528	expressed	T038	UMLS:C1171362
28121744	532	535	PMH	T038	UMLS:C0018915
28121744	536	552	biopsy specimens	T017	UMLS:C0677862
28121744	589	592	PMH	T038	UMLS:C0018915
28121744	593	603	tumor size	T082	UMLS:C0475440
28121744	614	623	treatment	T058	UMLS:C0087111